RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

Breast Cancer Research and Treatment

Volumn 135, Issue 3, 2012, Pages 771-780

  Canon, Jude ^a   Bryant, Rebecca ^a   Roudier, Martine ^b   Branstetter, Daniel G ^b   Dougall, William C ^b  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

Bone metastases; Breast cancer; Estrogen receptor positive; Osteoprotegerin; RANKL; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DESTRUCTION; BONE LESION; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER HORMONE THERAPY; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMICAL LABELING; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HINDLIMB; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR MICROENVIRONMENT;

EID: 84866543321     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2222-2     Document Type: Article

References (25)

1. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588-1594 (Pubitemid 27444031)
2. James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, Robertson JF (2003) Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features. Br J Cancer 89(4):660-665. doi:10.1038/sj.bjc. 6601198 (Pubitemid 37076169)
3. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16(1):67-78. doi:10.1016/j.ccr.2009.05.017
4. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22):4925-4935 (Pubitemid 46223998)
5. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97(1): 59-69
6. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584-593 (Pubitemid 37328925)
7. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655-1664
8. Blair JM, Zhou H, Seibel MJ, Dunstan CR (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3(1):41-49 (Pubitemid 43108833)
9. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61(11): 4432-4436 (Pubitemid 32685771)
10. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25(2):119-129. doi:10.1007/s10585-007-9127-1
11. Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC (2010) Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 46(6): 1613-1619. doi:10.1016/j.bone.2010.03.001
12. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC (2008) RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 7(7):2160-2169
13. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107(10):1235-1244 (Pubitemid 32494540)
14. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ (2006) The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 23:19-31 (Pubitemid 44576776)
15. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235-3258. doi:10.1200/JCO.2008.20.5179
16. Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI (2009) Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation. Mol Cell Biol 29(19):5306-5315. doi:10. 1128/MCB.01745-08
17. Kim TH, Shivdasani RA (2011) Genetic evidence that intestinal Notch functions vary regionally and operate through a common mechanism of Math1 repression. J Biol Chem 286(13): 11427-11433
18. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1):105-118 (Pubitemid 36223023)
19. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103-107. doi: 10.1038/nature09495
20. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98-102
21. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2): 6243s-6249s. doi:10.1158/1078-0432.CCR-06-0931 (Pubitemid 44703797)
22. Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC (2010) Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 9(7):539-550. doi:11266 [pii]
23. Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET (2008) RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 68(8): 820-829 (Pubitemid 351845213)
24. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132-5139. doi:10.1200/JCO.2010. 29.7101
25. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2011) Denosumab and bonemetastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(11)61226-9